Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 659

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 659
---
 respectively.

| For the six-month period ended 
 December 31,                   
 2024                           |     | Compensation amount 
                2023 |     |        As of 
 December 31, 
         2024 |     | Compensation Payable 
                 2023 |     |   |
|:-------------------------------|:----|--------------------:|:----|-------------:|:----|---------------------:|:----|:--|
| Short-term employee benefits   |     |             253,648 |     |       72,590 |     |              138,975 |     | — |
| Share-based payments           |     |             174,920 |     |            — |     |                    — |     | — |
| Total aggregate compensation   |     |             428,568 |     |       72,590 |     |              138,975 |     | — |

21. Segment information For management purposes, the Group’s business is managed in two operating and reportable segments: a direct -to -consumersegment named “Rewell” and a business -to -businesssegment named “Heritas Diagnostics”. Heritas Diagnostics Segment The Heritas Diagnostics segment provides clinical genetic tests, covering the fields of oncology, prenatal care, rare diseases and clinical gut health, and provides other genetic sequencing services. Rewell Segment The Rewell segment provides an at -homeDNA and microbiome test kits. Under IFRS 8 (Segment Information), operating segments are reported in a manner consistent with the internal reporting provided to the CODM which, in the case of the Group, is the Executive Team. The Executive Team is composed of a Chief Executive Officer, a Chief Science Officer, and a Chief Financial Officer. The CODM is responsible for allocating resources and assessing performance of the business.

F-115

Notes to Unaudited Interim Condensed Combined Financial Statements (Amounts in US Dollars, except otherwise indicated) 21. Segment information (cont.) The Executive Team measures the performance of the Group’s business by its “Gross Profit or Loss” as per the statement of operations. Business segment information for the six -monthended December 31, 2024 and 2023 is as follows:

| Six-month period ended December 31, 2024 |     |     Heritas 
 Diagnostics |   |     |   Rewell |   |     | Total as per the 
     statement of 
       operations |   |
|:-----------------------------------------